Literature DB >> 23812418

Functional characterization of Foxp3-specific spontaneous immune responses.

S K Larsen1, S Munir, A Woetmann, T M Frøsig, N Odum, I M Svane, J C Becker, M H Andersen.   

Abstract

Tumor-infiltrating CD4+CD25+ regulatory T cells (Tregs) are associated with an impaired prognosis in several cancers. The transcription factor forkhead box P3 (Foxp3) is generally expressed in Tregs. Here, we identify and characterize spontaneous cytotoxic immune responses to Foxp3-expressing cells in peripheral blood of healthy volunteers and cancer patients. These immune responses were directed against a HLA-A2-restricted peptide epitope derived from Foxp3. Foxp3-reactive T cells were characterized as cytotoxic CD8+ T cells. These cells recognized dendritic cells incubated with recombinant Foxp3 protein indicating that this protein was indeed internalized, processed and cross-presented in the context of HLA-A2. More importantly, however, Foxp3-specific T cells were able to specifically recognize Tregs. Similarly, Foxp3+ malignant T cells established from a Cutaneous T-cell lymphomas (CTCL) patient were readily killed by the Foxp3-specific cytotoxic T lymphocytes. The spontaneous presence of Foxp3-specific cytotoxic T-cell responses suggest a general role of such T cells in the complex network of immune regulation as such responses may eliminate Tregs, that is, suppression of the suppressors. Consequently, induction of Foxp3-specific cytotoxic T-cell responses appears as an attractive tool to boost spontaneous or therapeutically provoked immune responses, for example, for the therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812418     DOI: 10.1038/leu.2013.196

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 2.  Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Authors:  Mads Hald Andersen
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Mechanism by which the combination of SjCL3 and SjGAPDH protects against Schistosoma japonicum infection.

Authors:  Wenling Huang; Mengjie Gu; Wenjun Cheng; Shuhong Wang; Kaijie Li; Qin Ping Zhao; Zhenping Ming; Huifen Dong
Journal:  Parasitol Res       Date:  2020-10-20       Impact factor: 2.289

4.  T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.

Authors:  Niclas Olsson; Liora M Schultz; Lichao Zhang; Michael S Khodadoust; Rupa Narayan; Debra K Czerwinski; Ronald Levy; Joshua E Elias
Journal:  Proteomics       Date:  2018-04-18       Impact factor: 3.984

5.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

6.  Spontaneous presence of FOXO3-specific T cells in cancer patients.

Authors:  Stine Kiaer Larsen; Shamaila Munir Ahmad; Manja Idorn; Özcan Met; Evelina Martinenaite; Inge Marie Svane; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

Review 7.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

Review 8.  Anti-regulatory T cells.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-27       Impact factor: 9.623

Review 9.  The targeting of immunosuppressive mechanisms in hematological malignancies.

Authors:  M H Andersen
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

Review 10.  The T-win® technology: immune-modulating vaccines.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.